Cyclerion Therapeutics

(NASDAQ) CYCN

Current Price$2.96

Market Cap$13.25M

Since IPO (2019)-99%

5 Year-95%

1 Year-6%

1 Month-8%

Cyclerion Therapeutics Financials at a Glance

Market Cap

$13.25M

Revenue (TTM)

$1.99M

Net Income (TTM)

-$5.28M

EPS (TTM)

-$1.37

P/E Ratio

-2.23

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$2.96

Volume

24,448.815

Open

$2.98

Price

$2.96

Volume

24,448.815

Open

$2.98

Previous Close

$2.98

Daily Range

$2.96 - $3.09

52-Week Range

$1.03 - $8.48

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$2.96

Volume

24,448.815

Open

$2.98

Previous Close

$2.98

Daily Range

$2.96 - $3.09

52-Week Range

$1.03 - $8.48

Estimated Earnings Date

Aug 4, 2026

CYCN News

Why Cyclerion Therapeutics Is Crashing Today

George Budwell, PhDOct 14, 2020

Here’s Why Cyclerion Therapeutics Stock Plummeted Today

Brian Orelli, PhDOct 30, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclerion Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Regina Graul, PhD

Website

www.cyclerion.com

Headquarters

Cambridge, MA 02142, US

CYCN Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-68%

Return on Capital

-99%

Return on Assets

-62%

Earnings Yield

-44.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.25M

Shares Outstanding

4.33M

Volume

24.45K

Avg. Volume

4.51M

Financials (TTM)

Gross Profit

$2.07M

Operating Income

-$4.97M

EBITDA

-$4.97M

Operating Cash Flow

-$3.31M

Capital Expenditure

$0.00

Free Cash Flow

-$3.31M

Cash & ST Invst.

$3.24M

Total Debt

$0.00

Cyclerion Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$13.25M

N/A

Market Cap/Employee

$13.25M

N/A

Employees

N/A

Net Income

-$3.18M

-122.3%

EBITDA

-$3.21M

-120.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$2.82M

-22.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-62.03%

N/A

Return on Invested Capital

-99.03%

N/A

Free Cash Flow

-$1.24M

-28.3%

Operating Cash Flow

-$1.18M

-21.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PLRZPolyrizon Ltd.

PLRZPolyrizon Ltd.$12.99+0.93%

VYNEVYNE Therapeutics Inc.

VYNEVYNE Therapeutics Inc.$0.66-1.35%

TCRTAlaunos Therapeutics, Inc.

TCRTAlaunos Therapeutics, Inc.$2.28-6.56%

RADXRadiopharm Theranostics Limited

RADXRadiopharm Theranostics Limited$4.32-6.70%

XTLBXTL Biopharmaceuticals Ltd.

XTLBXTL Biopharmaceuticals Ltd.$2.06-7.62%

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.59-5.63%

ADXNAddex Therapeutics Ltd

ADXNAddex Therapeutics Ltd$5.86-8.44%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

Questions About CYCN

What is the current price of Cyclerion Therapeutics?

Cyclerion Therapeutics is trading at $2.98 per share.

What is the 52-week range for Cyclerion Therapeutics?

Over the past 52 weeks, Cyclerion Therapeutics has traded between $1.03 and $8.48.

How much debt does Cyclerion Therapeutics have?

As of the most recent reporting period, Cyclerion Therapeutics reported total debt of $0.00.

How much cash does Cyclerion Therapeutics have on hand?

Cyclerion Therapeutics reported $2.82M in cash and cash equivalents in its most recent financial results.

What is Cyclerion Therapeutics’s dividend yield?

Cyclerion Therapeutics does not currently have a dividend yield.

Cyclerion Therapeutics

Cyclerion Therapeutics Financials at a Glance

CYCN News

Why Cyclerion Therapeutics Is Crashing Today

Here’s Why Cyclerion Therapeutics Stock Plummeted Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cyclerion Therapeutics

CYCN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cyclerion Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CYCN

What is the current price of Cyclerion Therapeutics?

What is the 52-week range for Cyclerion Therapeutics?

How much debt does Cyclerion Therapeutics have?

How much cash does Cyclerion Therapeutics have on hand?

What is Cyclerion Therapeutics’s dividend yield?

Premium Investing Services